Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVFree Report) in a report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

The company has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The stock’s 50 day simple moving average is $0.14.

Nabriva Therapeutics Company Profile

(Get Free Report)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.

Read More

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.